The hormone replacement and therapeutic wellness market has been a growing concern for many companies, but Biote is seeing ...

Guidance shifted from reiterating 2025 revenues above $190 million and adjusted EBITDA above $50 million to projecting 2026 revenues above $190 million and adjusted EBITDA greater than $38 million, ...

IRVING, Texas--(BUSINESS WIRE)--biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading provider of hormone optimization, has announced the launch of a new Men’s Health Division with the ...

Corp. undertakes no obligation to update them in the future. Therefore, statements should not be relied upon as representing the company's views as of any subsequent date. For discussion of risks and ...

Biote Corp (BTMD) focuses on expanding its sales force and enhancing technology, despite facing revenue and margin pressures.

IRVING, Texas--(BUSINESS WIRE)-- biote Corp., (Nasdaq: BTMD) (“Biote” or the “Company”), a high growth, differentiated medical practice-building business within the hormone optimization space, today ...

Biote (NASDAQ: BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners’ patients, today announced financial results for the ...

COLUMBUS, GA, UNITED STATES, March 3, 2026 /EINPresswire.com/ -- OBGYN Specialists of Columbus is helping women better ...

As previously reported, Craig-Hallum initiated coverage of Biote (BTMD) with a Buy rating and $12 price target Consumer interest in next-gen therapies like hormone replacement therapy, or HRT, is ...

IRVING, Texas--(BUSINESS WIRE)-- Biote (BTMD) (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, ...

IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization ...